Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other...
11 KB (934 words) - 11:38, 21 October 2024
baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib, tofacitinib, and trelagliptin. BEACON Medicare...
5 KB (232 words) - 10:23, 8 March 2024
breast cancer Iomeron (iomeprol) - Non-ionic contrast medium Lenvima (lenvatinib) - Thyroid Cancer or Kidney Cancer Leqembi (lecanemab) - Alzheimer's disease...
12 KB (891 words) - 10:01, 2 July 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
121 KB (13,799 words) - 18:53, 22 October 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
93 KB (8,729 words) - 06:34, 10 November 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
42 KB (3,935 words) - 20:28, 27 October 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
24 KB (1,710 words) - 19:18, 30 August 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
12 KB (966 words) - 04:46, 15 July 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
26 KB (2,420 words) - 02:40, 26 September 2024
after resection, or to relieve pain from bone metastasis. Sorafenib and lenvatinib are approved for advanced metastatic thyroid cancer. Numerous agents are...
59 KB (5,276 words) - 15:48, 2 November 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
73 KB (6,455 words) - 04:22, 2 November 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
43 KB (4,651 words) - 13:41, 27 July 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
13 KB (1,177 words) - 01:44, 4 November 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
10 KB (600 words) - 04:23, 25 October 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
15 KB (976 words) - 17:10, 20 October 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
69 KB (6,102 words) - 23:51, 21 October 2024
triple-negative breast cancer Avalglucosidase alfa Genzyme late-onset Pompe disease Lenvatinib Eisai Inc advanced renal cell carcinoma, used in combination with pembrolizumab...
34 KB (180 words) - 17:05, 14 October 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
34 KB (3,021 words) - 12:39, 5 August 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
10 KB (1,179 words) - 18:31, 8 August 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
29 KB (2,696 words) - 14:16, 27 July 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
22 KB (1,993 words) - 23:37, 23 March 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
25 KB (2,086 words) - 02:24, 16 July 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
22 KB (1,994 words) - 08:45, 4 November 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
64 KB (7,432 words) - 08:21, 28 October 2024
can also be used in the treatment for breast cancer and kidney cancer. Lenvatinib and vandetanib are used for the treatment of progressive and locally advanced...
51 KB (4,735 words) - 08:15, 2 January 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
36 KB (3,929 words) - 18:22, 21 September 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
10 KB (1,131 words) - 19:14, 31 March 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
69 KB (6,089 words) - 12:41, 9 November 2024
everolimus and was approved by the FDA as a second-line treatment in 2016. Lenvatinib in combination with everolimus was approved in 2016 for patients who have...
56 KB (5,187 words) - 04:02, 20 September 2024
Kinase inhibitors: Agerafenib Avapritinib Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib...
60 KB (6,879 words) - 14:26, 16 July 2024